한글목차

결막염 시장은 2023년 48억 달러로 평가되었고, 2024-2033년 연평균 4.1% 성장하여 2033년에는 72억 달러에 이를 것으로 예상됩니다.

결막염은 결막(흰자위와 눈꺼풀 안쪽을 덮고 있는 얇고 투명한 막)에 염증을 일으키는 가장 흔한 안구 감염 질환입니다. 바이러스나 세균 감염, 알레르기 항원, 자극제 등 다양한 요인에 의해 발생합니다. 이 증상은 충혈, 가려움증, 부종, 눈에서 분비물 등의 증상이 특징입니다. 결막염은 종종 불편하고 전염성이 있지만 일반적으로 치료할 수 있으며 심각한 합병증을 유발하는 경우는 드뭅니다.

세계 결막염 시장의 성장은 결막염의 높은 유병률, 특히 결막염이 자주 발생하는 지역의 높은 유병률과 치료 및 예방 조치에 대한 수요 증가에 기인하며, Medscape(의료 뉴스, 임상시험 보도 및 의약품 업데이트에 대한 액세스를 제공하는 웹 사이트)가 2024년에 발표한 조사에 따르면, 미국에서는 연간 600만 건의 바이러스성 결막염이 새롭게 발생하는 것으로 추정됩니다. 공해, 꽃가루 등 환경적 요인으로 인한 알레르기성 결막염 환자가 증가하면서 관련 치료제에 대한 수요가 증가하고 있습니다. 또한, 특히 학교나 대중교통과 같은 혼잡한 환경에서는 바이러스 및 세균 감염이 빈번하게 발생하기 때문에 효과적인 치료 옵션에 대한 필요성이 증가하고 있습니다. 또한, 소비자의 인식이 높아지고 처방전 없이도 쉽게 접근할 수 있는 편의성으로 인해 시중에서 판매되는 아이케어 제품에 대한 선호도가 높아진 것도 시장 성장에 크게 기여하고 있습니다. 또한, 노인 인구의 급격한 증가도 시장 성장을 가속하고 있습니다. 이는 결막을 포함한 눈의 조직이 자연적으로 퇴화한다는 사실에 기인합니다. 이로 인해 노인의 눈은 자극, 감염, 염증에 취약해져 결막염과 같은 증상이 발생할 가능성이 높아집니다. 개인 맞춤형 의료 트렌드는 개별 환자 프로파일과 특정 결막염의 원인에 따라 맞춤형 치료를 촉진함으로써 결막염 시장에 더 많은 영향을 미치고 있습니다. 그러나 많은 사람들이 결막염을 자가 진단하고 일반의약품이나 가정상비약으로 자가 치료하는 경우가 많은데, 이는 잘못된 치료와 증상 악화로 이어질 수 있습니다. 잘못된 진단은 부적절한 약물 사용으로 이어질 수 있으며, 이는 세계 시장의 주요 저해요인으로 작용하고 있습니다. 또한 의료 서비스 및 안과 전문의에 대한 접근성이 제한되어 결막염의 적시 진단 및 치료를 방해하고 합병증 발생률이 높아져 시장 성장을 억제합니다. 반대로 제약 연구의 발전으로 결막염에 대한 새로운 항균제 및 항염증제 등 보다 효과적인 새로운 치료법이 개발되고 있습니다. 또한, 결막염 진단 및 치료 계획의 정확성과 속도를 향상시키기 위해 진단 도구에 AI와 ML을 통합하는 것은 시장 성장에 새로운 길을 제시할 것으로 예상됩니다.

세계 결막염 시장은 유형, 질병 유형, 최종 사용자, 지역으로 분류됩니다. 유형별로 시장은 진단과 치료로 나뉩니다. 진단 부문은 다시 신체 검사 및 임상시험으로 세분화됩니다. 치료 부문은 다시 항생제, 항바이러스제, 항알레르기제, 인공누액으로 세분화됩니다. 질병 유형에 따라 시장은 알레르기성 결막염, 세균성 결막염, 바이러스성 결막염으로 나뉩니다. 알레르기성 결막염은 다시 계절성 알레르기성 결막염과 연중 알레르기성 결막염으로 나뉩니다. 최종 사용자에 따라 병원 및 클리닉, 전문 안과 클리닉, 기타로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 치료 부문이 2023년 시장에서 가장 큰 점유율을 차지했습니다.

질병 유형별로는 알레르기성 결막염 부문이 2023년 시장을 주도했습니다.

최종 사용자별로는 병원 및 클리닉이 2023년 주요 부문으로 부상했습니다.

지역별로는 북미가 2023년 결막염 시장의 주요 주주이며, 예측 기간 동안 그 우위를 유지할 것으로 예상됩니다.

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 구도

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 결막염 시장 : 유형별

• 시장 개요
• 진단
  • 신체 시험
  • 임상시험
• 치료
  • 항생제
  • 항바이러스제
  • 항알레르기제
  • 인공누액

제5장 결막염 시장 : 질환 유형별

• 시장 개요
• 알레르기성 결막염
  • 계절성 알레르기성 결막염
  • 연중성 알레르기성 결막염
• 세균성 결막염
• 바이러스성 결막염

제6장 결막염 시장 : 최종사용자별

• 시장 개요
• 병원 및 클리닉
• 전문 안과 클리닉
• 기타

제7장 정신분열증 시장 결막염 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국 결막염 시장
  • 캐나다 결막염 시장
  • 멕시코 결막염 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일 결막염 시장
  • 프랑스 결막염 시장
  • 영국 결막염 시장
  • 이탈리아 결막염 시장
  • 스페인 결막염 시장
  • 기타 유럽 결막염 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본 결막염 시장
  • 중국 결막염 시장
  • 인도 결막염 시장
  • 호주 결막염 시장
  • 한국 결막염 시장
  • 기타 아시아태평양 결막염 시장
• 라틴아메리카/중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질 결막염 시장
  • 사우디아라비아 결막염 시장
  • 남아프리카공화국 결막염 시장
  • 기타 라틴아메리카/중동 및 아프리카 결막염 시장

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 개요

• AFT Pharmaceuticals
• Alembic Pharmaceuticals Ltd
• Johnson And Johnson Services Inc
• Ocular Therapeutics, Inc
• Cipla, Inc.
• Jabs Biotech Pvt. Ltd.
• Spectra Vision Care Pvt. Ltd
• Teva Pharmaceutical Industries Ltd
• Grevis Pharmaceutical Private Limited
• Bausch Health Companies Inc

영문목차

The conjunctivitis market was valued at $4.8 billion in 2023, and is projected to reach $7.2 billion by 2033, growing at a CAGR of 4.1% from 2024 to 2033.

Conjunctivitis is the most prevalent eye infection that causes the inflammation of the conjunctiva-the thin, transparent membrane that lines the white part of the eye and the inner surface of the eyelids. It can be caused by various factors, including viral or bacterial infections, allergens, or irritants. This condition is characterized by symptoms such as redness, itching, swelling, and discharge from the eye. While often uncomfortable and contagious, conjunctivitis is typically treatable and rarely causes serious complications.

The growth of the global conjunctivitis market is driven by high prevalence of conjunctivitis, particularly in regions with frequent outbreaks, drives demand for treatment and preventive measures. According to a 2024 study published by Medscape-website providing access to medical news, clinical trial coverage, drug updates-an estimated 6 million new cases of viral conjunctivitis occur annually in the U.S. Increase in cases of allergic conjunctivitis due to environmental factors, such as pollution and pollen, boosts the demand for relevant therapies. Moreover, frequent outbreaks of viral or bacterial infections, especially in crowded settings like schools and public transport, foster the need for effective treatment options. Furthermore, increase in preference for over-the-counter eye care products, driven by increased consumer awareness and the convenience of accessing these products without prescription, notably contributes toward the market growth. In addition, surge in geriatric population propels the market growth. This is attributed to the fact that the tissues in the eyes, including the conjunctiva, undergoes natural degeneration. This makes the eyes of aged individuals more prone to irritation, infections, and inflammation, leading to a higher likelihood of developing conditions like conjunctivitis, which augments the demand for specialized treatments. The trend toward personalized medicine is further impacting the conjunctivitis market by promoting tailored treatments based on individual patient profiles and specific conjunctivitis causes. However, many individuals self-diagnose and self-treat conjunctivitis with over-the-counter products or home remedies, which can lead to incorrect treatment and potential worsening of the condition. Misdiagnosis can also result in inappropriate use of medications, which acts as the key deterrent factor of the global market. In addition, limited access to healthcare services and eye care professionals hinders timely diagnosis and treatment of conjunctivitis, leading to higher rates of complications, thus restraining the market growth. On the contrary, advances in pharmaceutical research are leading to the development of new and more effective therapies, including novel antimicrobial agents and anti-inflammatory treatments for conjunctivitis. Furthermore, integration of AI and ML in diagnostic tools to improve the accuracy and speed of conjunctivitis diagnosis and treatment planning is anticipated to offer new avenues for the market growth.

The global conjunctivitis market is segmented into type, disease type, end user, and region. On the basis of the type, the market is bifurcated into diagnosis and treatment. The diagnosis segment is further segmented into physical examination and laboratory tests. The treatment segment is further classified into antibiotics, antiviral, anti-allergic, and artificial tears. Depending on disease type, the market is divided into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment is further categorized into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. As per end user, the market is classified into hospitals & clinics, specialty eye clinics, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the treatment segment accounted for the largest share of the market in 2023.

On the basis of disease type, the allergic conjunctivitis segment dominated the market in 2023.

Depending on end user, hospital & clinics emerged as the leading segment in 2023.

Region wise, North America was the major shareholder in the conjunctivitis market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global conjunctivitis market include AFT Pharmaceuticals, Alembic Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Ocular Therapeutics, Inc., Cipla, Inc., Jabs Biotech Pvt. Ltd., Spectra Vision Care Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Grevis Pharmaceutical Private Limited, and Bausch Health Companies Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Diagnosis
  • Physical Examination
  • Laboratory Tests
• Treatment
  • Antibiotics
  • Antiviral
  • Anti-allergic
  • Artificial Tears

By Disease Type

• Allergic Conjunctivitis
  • Seasonal Allergic Conjunctivitis
  • Perennial Allergic Conjunctivitis
• Bacterial Conjunctivitis
• Viral Conjunctivitis

By End User

• Hospitals and Clinics
• Specialty Eye Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• AFT Pharmaceuticals
• Alembic Pharmaceuticals Ltd
• Johnson & Johnson Services Inc
• Ocular Therapeutics, Inc
• Cipla, Inc.
• Jabs Biotech Pvt. Ltd.
• Spectra Vision Care Pvt. Ltd
• Teva Pharmaceutical Industries Ltd
• Grevis Pharmaceutical Private Limited
• Bausch Health Companies Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: CONJUNCTIVITIS MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. Diagnosis
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
  • 4.2.5. Physical Examination
    • 4.2.5.1. Market Size and Forecast
  • 4.2.6. Laboratory Tests
    • 4.2.6.1. Market Size and Forecast
• 4.3. Treatment
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
  • 4.3.5. Antibiotics
    • 4.3.5.1. Market Size and Forecast
  • 4.3.6. Antiviral
    • 4.3.6.1. Market Size and Forecast
  • 4.3.7. Anti-allergic
    • 4.3.7.1. Market Size and Forecast
  • 4.3.8. Artificial Tears
    • 4.3.8.1. Market Size and Forecast

CHAPTER 5: CONJUNCTIVITIS MARKET, BY DISEASE TYPE

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Disease Type
• 5.2. Allergic Conjunctivitis
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
  • 5.2.5. Seasonal Allergic Conjunctivitis
    • 5.2.5.1. Market Size and Forecast
  • 5.2.6. Perennial Allergic Conjunctivitis
    • 5.2.6.1. Market Size and Forecast
• 5.3. Bacterial Conjunctivitis
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Viral Conjunctivitis
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: CONJUNCTIVITIS MARKET, BY END USER

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By End User
• 6.2. Hospitals And Clinics
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Specialty Eye Clinics
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Others
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CONJUNCTIVITIS MARKET, BY REGION

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By Region
• 7.2. North America
  • 7.2.1. Key Market Trends and Opportunities
  • 7.2.2. Market Size and Forecast, By Type
  • 7.2.3. Market Size and Forecast, By Disease Type
  • 7.2.4. Market Size and Forecast, By End User
  • 7.2.5. Market Size and Forecast, By Country
  • 7.2.6. U.S. Conjunctivitis Market
    • 7.2.6.1. Market Size and Forecast, By Type
    • 7.2.6.2. Market Size and Forecast, By Disease Type
    • 7.2.6.3. Market Size and Forecast, By End User
  • 7.2.7. Canada Conjunctivitis Market
    • 7.2.7.1. Market Size and Forecast, By Type
    • 7.2.7.2. Market Size and Forecast, By Disease Type
    • 7.2.7.3. Market Size and Forecast, By End User
  • 7.2.8. Mexico Conjunctivitis Market
    • 7.2.8.1. Market Size and Forecast, By Type
    • 7.2.8.2. Market Size and Forecast, By Disease Type
    • 7.2.8.3. Market Size and Forecast, By End User
• 7.3. Europe
  • 7.3.1. Key Market Trends and Opportunities
  • 7.3.2. Market Size and Forecast, By Type
  • 7.3.3. Market Size and Forecast, By Disease Type
  • 7.3.4. Market Size and Forecast, By End User
  • 7.3.5. Market Size and Forecast, By Country
  • 7.3.6. Germany Conjunctivitis Market
    • 7.3.6.1. Market Size and Forecast, By Type
    • 7.3.6.2. Market Size and Forecast, By Disease Type
    • 7.3.6.3. Market Size and Forecast, By End User
  • 7.3.7. France Conjunctivitis Market
    • 7.3.7.1. Market Size and Forecast, By Type
    • 7.3.7.2. Market Size and Forecast, By Disease Type
    • 7.3.7.3. Market Size and Forecast, By End User
  • 7.3.8. UK Conjunctivitis Market
    • 7.3.8.1. Market Size and Forecast, By Type
    • 7.3.8.2. Market Size and Forecast, By Disease Type
    • 7.3.8.3. Market Size and Forecast, By End User
  • 7.3.9. Italy Conjunctivitis Market
    • 7.3.9.1. Market Size and Forecast, By Type
    • 7.3.9.2. Market Size and Forecast, By Disease Type
    • 7.3.9.3. Market Size and Forecast, By End User
  • 7.3.10. Spain Conjunctivitis Market
    • 7.3.10.1. Market Size and Forecast, By Type
    • 7.3.10.2. Market Size and Forecast, By Disease Type
    • 7.3.10.3. Market Size and Forecast, By End User
  • 7.3.11. Rest of Europe Conjunctivitis Market
    • 7.3.11.1. Market Size and Forecast, By Type
    • 7.3.11.2. Market Size and Forecast, By Disease Type
    • 7.3.11.3. Market Size and Forecast, By End User
• 7.4. Asia-Pacific
  • 7.4.1. Key Market Trends and Opportunities
  • 7.4.2. Market Size and Forecast, By Type
  • 7.4.3. Market Size and Forecast, By Disease Type
  • 7.4.4. Market Size and Forecast, By End User
  • 7.4.5. Market Size and Forecast, By Country
  • 7.4.6. Japan Conjunctivitis Market
    • 7.4.6.1. Market Size and Forecast, By Type
    • 7.4.6.2. Market Size and Forecast, By Disease Type
    • 7.4.6.3. Market Size and Forecast, By End User
  • 7.4.7. China Conjunctivitis Market
    • 7.4.7.1. Market Size and Forecast, By Type
    • 7.4.7.2. Market Size and Forecast, By Disease Type
    • 7.4.7.3. Market Size and Forecast, By End User
  • 7.4.8. India Conjunctivitis Market
    • 7.4.8.1. Market Size and Forecast, By Type
    • 7.4.8.2. Market Size and Forecast, By Disease Type
    • 7.4.8.3. Market Size and Forecast, By End User
  • 7.4.9. Australia Conjunctivitis Market
    • 7.4.9.1. Market Size and Forecast, By Type
    • 7.4.9.2. Market Size and Forecast, By Disease Type
    • 7.4.9.3. Market Size and Forecast, By End User
  • 7.4.10. South Korea Conjunctivitis Market
    • 7.4.10.1. Market Size and Forecast, By Type
    • 7.4.10.2. Market Size and Forecast, By Disease Type
    • 7.4.10.3. Market Size and Forecast, By End User
  • 7.4.11. Rest of Asia-Pacific Conjunctivitis Market
    • 7.4.11.1. Market Size and Forecast, By Type
    • 7.4.11.2. Market Size and Forecast, By Disease Type
    • 7.4.11.3. Market Size and Forecast, By End User
• 7.5. LAMEA
  • 7.5.1. Key Market Trends and Opportunities
  • 7.5.2. Market Size and Forecast, By Type
  • 7.5.3. Market Size and Forecast, By Disease Type
  • 7.5.4. Market Size and Forecast, By End User
  • 7.5.5. Market Size and Forecast, By Country
  • 7.5.6. Brazil Conjunctivitis Market
    • 7.5.6.1. Market Size and Forecast, By Type
    • 7.5.6.2. Market Size and Forecast, By Disease Type
    • 7.5.6.3. Market Size and Forecast, By End User
  • 7.5.7. Saudi Arabia Conjunctivitis Market
    • 7.5.7.1. Market Size and Forecast, By Type
    • 7.5.7.2. Market Size and Forecast, By Disease Type
    • 7.5.7.3. Market Size and Forecast, By End User
  • 7.5.8. South Africa Conjunctivitis Market
    • 7.5.8.1. Market Size and Forecast, By Type
    • 7.5.8.2. Market Size and Forecast, By Disease Type
    • 7.5.8.3. Market Size and Forecast, By End User
  • 7.5.9. Rest of LAMEA Conjunctivitis Market
    • 7.5.9.1. Market Size and Forecast, By Type
    • 7.5.9.2. Market Size and Forecast, By Disease Type
    • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top Winning Strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. AFT Pharmaceuticals
  • 9.1.1. Company Overview
  • 9.1.2. Key Executives
  • 9.1.3. Company Snapshot
  • 9.1.4. Operating Business Segments
  • 9.1.5. Product Portfolio
  • 9.1.6. Business Performance
  • 9.1.7. Key Strategic Moves and Developments
• 9.2. Alembic Pharmaceuticals Ltd
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Operating Business Segments
  • 9.2.5. Product Portfolio
  • 9.2.6. Business Performance
  • 9.2.7. Key Strategic Moves and Developments
• 9.3. Johnson And Johnson Services Inc
  • 9.3.1. Company Overview
  • 9.3.2. Key Executives
  • 9.3.3. Company Snapshot
  • 9.3.4. Operating Business Segments
  • 9.3.5. Product Portfolio
  • 9.3.6. Business Performance
  • 9.3.7. Key Strategic Moves and Developments
• 9.4. Ocular Therapeutics, Inc
  • 9.4.1. Company Overview
  • 9.4.2. Key Executives
  • 9.4.3. Company Snapshot
  • 9.4.4. Operating Business Segments
  • 9.4.5. Product Portfolio
  • 9.4.6. Business Performance
  • 9.4.7. Key Strategic Moves and Developments
• 9.5. Cipla, Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Key Executives
  • 9.5.3. Company Snapshot
  • 9.5.4. Operating Business Segments
  • 9.5.5. Product Portfolio
  • 9.5.6. Business Performance
  • 9.5.7. Key Strategic Moves and Developments
• 9.6. Jabs Biotech Pvt. Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Key Executives
  • 9.6.3. Company Snapshot
  • 9.6.4. Operating Business Segments
  • 9.6.5. Product Portfolio
  • 9.6.6. Business Performance
  • 9.6.7. Key Strategic Moves and Developments
• 9.7. Spectra Vision Care Pvt. Ltd
  • 9.7.1. Company Overview
  • 9.7.2. Key Executives
  • 9.7.3. Company Snapshot
  • 9.7.4. Operating Business Segments
  • 9.7.5. Product Portfolio
  • 9.7.6. Business Performance
  • 9.7.7. Key Strategic Moves and Developments
• 9.8. Teva Pharmaceutical Industries Ltd
  • 9.8.1. Company Overview
  • 9.8.2. Key Executives
  • 9.8.3. Company Snapshot
  • 9.8.4. Operating Business Segments
  • 9.8.5. Product Portfolio
  • 9.8.6. Business Performance
  • 9.8.7. Key Strategic Moves and Developments
• 9.9. Grevis Pharmaceutical Private Limited
  • 9.9.1. Company Overview
  • 9.9.2. Key Executives
  • 9.9.3. Company Snapshot
  • 9.9.4. Operating Business Segments
  • 9.9.5. Product Portfolio
  • 9.9.6. Business Performance
  • 9.9.7. Key Strategic Moves and Developments
• 9.10. Bausch Health Companies Inc
  • 9.10.1. Company Overview
  • 9.10.2. Key Executives
  • 9.10.3. Company Snapshot
  • 9.10.4. Operating Business Segments
  • 9.10.5. Product Portfolio
  • 9.10.6. Business Performance
  • 9.10.7. Key Strategic Moves and Developments